

IFW



**PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Robert Parsons, *et al.*

Serial No.: 10/721,031

Filed: November 24, 2003

For: STABLE COMPOSITIONS  
MEASURING HUMAN  
NATRURETIC PEPTIDES

Examiner: Not yet assigned

Group Art Unit: 1641

Case No.: 7098.US.P1


Date: August 18, 2004

**Certificate of Mailing under 37 CFR §1.8(a):**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450, on:

Date of Deposit: August 18, 2004

  
Michele M. Bonke

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is the Information Disclosure Statement of Nonprovisional Application of Robert Parsons, *et al.* for Serial No. 10/721,031 filed, November 24, 2003.

Also enclosed are:


PTO Form 1449 (in duplicate)  
Copies of Eight References  
Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. **A duplicate copy of this sheet is enclosed.**

23492

ABBOTT LABORATORIES  
Telephone: (847) 937-8284  
Facsimile: (847) 938-2623

Respectfully submitted,  
Robert Parsons, *et al.*

  
Regina M. Anderson  
Registration No. 35,820  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Certificate of Mailing (37 CFR 1.8(a))

Applicant: Robert Parsons, et al.

Serial No.: 10/721,031

Filed: November 24, 2003

Title: STABLE COMPOSITIONS  
FOR MEASURING HUMAN NATRIURETIC  
PEPTIDES

Group Art: 1641

Examiner: (not yet assigned)

Case No.: 7098.US.P1

Date: August 18, 2004

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450, on:

Date of Deposit: August 18, 2004

  
Michele M. Bonke

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 C.F.R. § 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents, except for United States patents, are attached.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES  
Customer Number 23492  
Telephone: (847) 937-8284  
Facsimile: (847) 938-2623

Respectfully submitted,  
Robert Parsons, et al.

  
Regina M. Anderson  
Registration No. 35,820  
Attorney for Applicants



DATE: August 18, 2004

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98 (b))	ATTY. DOCKET NO. <b>7098.US.P1</b>	SERIAL NO. <b>10/721,031</b>
	APPLICANT(S) <b>Robert Parsons, et al.</b>	
	FILING DATE <b>11/24/2003</b>	GROUP <b>1641</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	5,358,691	10/25/94	Clark, et al.			
	A2	6,376,207	4/23/02	Mischak, et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Motwani, et al., "Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infraction". The Lancet, 341: 1109-1113, (1997).
	C2	Cataliotti, et al., "Circulating Natriuretic Peptide Concentrations in Patients With End-Stage Renal Disease: Role of Brain Natriuretic Peptide as a Biomaker for Ventricular Remodeling". Mayo Foundation for Medical Education and Research, 76: 1111-1119, (2001).
	C3	Mukoyama, et al., "Brain Natriuretic Peptide as a Novel Cardiac Hormone in Humans." Journal Clinical Investigation, 87: 11402-11412, (1991).
	C4	Yandle, T.G., "MINISYMPOSIUM: THE NATRIURETIC PEPTIDE HORMONES; Biochemistry of natriuretic peptides", Journal of Internal Medicine." 235: 561-576, (1994).
	C5	Murdoch, et al., "Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice". Heart 1997; 78:594-597.
	C6	Davidson et al., " Brain natriuretic peptide". Journal of Hypertension, 1994; 12:329-336.
	C7	Yoshiyoshi, et al., "Increased Plasma Levels of Brain Natriuretic Peptide in Hypertrophic Cardiomyopathy". The New England Journal of Medicine, 1993; Vol. 32, No. 6, pp. 433-435.
	C8	Shimizu, et al., "Molecular forms of human brain natriuretic peptide in plasma". Clinica Chimica Acta, 2002; 129 - 135.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)